Preferred Label : Cevidoplenib Dimesylate;
NCIt definition : The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine
kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon
oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking
Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including
macrophages, neutrophils, mast cells, natural killer (NK) cells and B-cells. This
leads to the inhibition of the activation of these inflammatory cells, and the related
inflammatory responses and tissue damage. SYK, a non-receptor cytoplasmic protein
tyrosine kinase widely expressed in hematopoietic cells, plays a key role in Fc receptor
and B-cell receptor signaling in inflammatory cells. It is involved in coupling activated
immunoreceptors, such as Fc receptors and B-cell receptors, to signal downstream events
that mediate diverse cellular responses, including proliferation, differentiation,
and phagocytosis, which are important for allergic and antibody-mediated immune diseases
such as immune thrombocytopenia (ITP).;
UNII : B6NX06SK0J;
InChIKey : KGZICKLRNSIYNH-TXEPZDRESA-N;
CAS number : 2043659-93-2;
Molecule name : SKI O 703; SKI-O-703;
NCI Metathesaurus CUI : CL1383220;
Origin ID : C170949;
UMLS CUI : C5418897;
Semantic type(s)
- concept_is_in_subset
- has_free_acid_or_base_form
- has_target
- is_salt_form_of
